Video

Genomic Classifier in Prostate Cancer: Post Radical Prostatectomy VL

Precision Risk Assessment in Prostate Cancer: Growing Utility in NCCN Guidelines - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...
Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach - Katie Murray and Anne Lizardi-Calvaresi Details Katie Murray and Anne Lizardi-Calvaresi discuss a clinical pathway approach for using the Decipher prostate cancer genomic classifier. Reviewing the level-one evidence described in the NCCN guidelines, they discuss best practices as clinicians integrate prostate cancer genomic classifiers into the care of their patients. They highlight how the test is integrated into the workflow for patient navig...
PORTOS as a Predictive Biomarker to Help Personalize Radiotherapy Dose in the Postoperative Setting, in the SAKK 09/10 Trial - Alan Dal Pra Details Alan Dal Pra joins Alicia Morgans in a discussion on the prognostic and predictive performance of the 24-gene Post-Operative Radiation Therapy Outcome Score, the PORTOS signature in the phase 3 randomized clinical trial assessing dose escalation after radical prostatectomy, the SAKK 09/10 trial. The SAKK 09/10 was a multicenter, randomized phase III trial performed across 24 centers in Switzerland...
Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross Details In this discussion, Alicia Morgans and Ashley Ross discuss men in the adjuvant setting with the highest risk of prostate cancer metastasis by genomic stratification. They focus their discussion on Decipher molecular testing after prostatectomy and the Phase III ERADICATE study. The ERADICATE trial was presented at this year's ASCO meeting. Biographies: Ashley Ross, MD, Ph.D., Associate Professor,...
Rationale for the Use of Decipher® RP Genomic Classifier to Inform Treatment - Ashley Ross Details Alicia Morgans and Ashley Ross discuss Decipher® RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher® is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic pr...
Decipher® Biopsy and Decipher® for Prostatectomy in Clinical Practice- Ashley Ross Details Alicia Morgans and Ashley Ross discuss Decipher® testing, both Decipher® Biopsy and Decipher® for prostatectomy specimens, and how to integrate these tests into standard clinical practice. Decipher® is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to st...
The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal Details Alicia Morgans sits down with Brandon Mahal to explore the complexities of using salvage systemic therapy alongside salvage radiation therapy for post-prostatectomy patients. Dr. Mahal outlines the current conundrum: whether to administer Androgen Deprivation Therapy (ADT) and for how long, especially for men with high PSAs post-surgery. He references multiple randomized trials that offer conflict...
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra Details Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor and A...
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra Details In this UroToday presentation Daniel Spratt, MD, and Alan Dal Pra, MD, share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone therapy with postoperative radiation therapy and the clinical implications for Decipher®. Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer...
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt Details Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the RTOG...

Genomic Classifier in Prostate Cancer: Post Radical Prostatectomy VL

Login